Citations

Clear

6273 citation(s) found for "To, Andrew".

Alterations in Aquaporin‐4‐IgG Serostatus in 986 Patients: A Laboratory‐Based Longitudinal Analysis
Majed, Masoud , Valencia-Sánchez, Cristina , Bennett, Jeffrey L. , Fryer, James P., Mulligan, Martin D., Redenbaugh, Vyankya, McKeon, Andrew , Mills, John R. , Wingerchuk, Dean M. , Lennon, Vanda A. , Weinshenker, Brian G. , Chen, John J. , Pittock, Sean J. , Kunchok, Amy , Pittock, S J , Fryer, James, Pittock, Sean J , Bennett, Jeffrey L , Weinshenker, Brian G , McKeon, Andrew , Chen, John J , Valencia Sanchez, Cristina , Flanagan, Eoin P.

Mayo Clinic

Annals of Neurology | June 14, 2023 | Volume: 94 | Issue: 4 | Pages: 727-735

10.1002/ana.26722 | PMID 37314750 Get It

Objective This study was undertaken to investigate factors associated with aquaporin‐4 (AQP4)‐IgG serostatus change using a large serological database. Methods This retrospective study utilizes Mayo Clinic Neuroimmunology Laboratory data from 2007 to 2021. We included all patients with ≥2 AQP4‐IgG tests (by cell‐based assay). The frequency and clinical factors associated with serostatus change were evaluated. Multivariable logistic regression analysis examined whether age, sex, or initial titer was associated with serostatus change. Results There were 933 patients who had ≥2 AQP4‐IgG tests with an initial positive result. Of those, 830 (89%) remained seropositive and 103 (11%) seroreverted to negative. Median interval to seroreversion was 1.2 years (interquartile range [IQR] = 0.4–3.5). Of those with sustained seropositivity, titers were stable in 92%. Seroreversion was associated with age ≤ 20 years (odds ratio [OR] = 2.25; 95% confidence interval [CI] = 1.09–4.63; p = 0.028) and low initial titer of ≤1:100 (OR = 11.44, 95% CI = 3.17–41.26, p < 0.001), and 5 had clinical attacks despite seroreversion. Among 62 retested after seroreversion, 50% returned to seropositive (median = 224 days, IQR = 160–371). An initial negative AQP4‐IgG test occurred in 9,308 patients. Of those, 99% remained seronegative and 53 (0.3%) seroconverted at a median interval of 0.76 years (IQR = 0.37–1.68). Interpretation AQP4‐IgG seropositivity usually persists over time with little change in titer. Seroreversion to negative is uncommon (11%) and associated with lower titers and younger age. Seroreversion was often transient, and attacks occasionally occurred despite prior seroreversion, suggesting it may not reliably reflect disease activity. Seroconversion to positive is rare (<1%), limiting the utility of repeat testing in seronegative patients unless clinical suspicion is high. ANN NEUROL 2023;94:727–735
#3125 EXTERNAL VALIDATION OF A NOVEL MULTIMARKER GFR ESTIMATING EQUATION
Tio, Maria Clarissa , Zhu, Xiaoqian , Hall, Michael E. , Mosely, T., Lirette, Seth T. , Rule, Andrew D. , Butler, Kenneth R. , Dossabhoy, Neville R. , Shafi, Tariq

Mayo Clinic

Nephrology Dialysis Transplantation | June 14, 2023 | Volume: 38 | Issue: Supplement_1 | Pages: No page available

10.1093/ndt/gfad063c_3125 Get It

Abstract Background and Aims The use of multiple markers may improve the accuracy in glomerular filtration rate (GFR) estimation especially when the interpretation of creatinine and cystatin C is limited. We sought to externally validate a recently developed multi-marker nuclear magnetic resonance (NMR)-based estimated GFR equation (eGFR-NMR) using the biracial Genetic Epidemiology Network of Arteriopathy cohort. Method We included 224 sex, race/ethnicity, and mGFR-category-matched participants. GFR was measured using urinary clearance of iothalamate (mGFR). We calculated eGFR-NMR using serum creatinine, valine, myo-inositol, and cystatin C, age, and sex. We compared the reliability of eGFR-NMR with current eGFR equations (2021 Chronic Kidney Disease Epidemiology Collaboration equations for creatinine [eGFR-Cr] and creatinine with cystatin C [eGFR-Cr-CysC]) using median bias, precision, and accuracy metrics. In particular, we evaluated its performance in age, sex, and race subgroups. Results In the overall cohort, mean age was 63 (±8) years, 54% were females, 49% were Black individuals, and mean mGFR was 78.7 (±24.3) ml/min/1.73 m2. eGFR-NMR overestimated mGFR by 2 mL/min/1.73 m2 (95% CI, 4 to 0.7) while eGFR-Cr-CysC underestimated mGFR by −5 mL/min/1.73 m2 (95% CI, −2 to −7). All equations had acceptable accuracy metrics. When stratified by age, sex, and race, eGFR-NMR performed the best among Black males age &lt;65 years compared to current equations (Figure 1). In this subgroup, eGFR-NMR was unbiased (bias, 2mL/min/1.73 m2 [95% CI, -3 to 10]) compared to substantial biases of eGFR-Cr (bias, 17 mL/min/1.73 m2 [95% CI, 9 to 24]) and eGFR-Cr-CysC (bias, 15 mL/min/1.73 m2 [95% CI, 6 to 20]). In other subgroups, measures of accuracy for eGFR-NMR, eGFR-Cr, eGFR-Cr-CysC were generally similar. Conclusion eGFR-NMR can be used to estimate mGFR and was more accurate than CKD-EPI equations among Black males age &lt;65 years.
#4573 IMPACT OF A REMOTE PATIENT MONITORING ON UNPLANNED READMISSIONS IN ACUTE KIDNEY INJURY SURVIVORS
Kattah, Andrea G. , Ferguson, Jennifer, Rosedahl, Jordan K., Frazee, Erin N. , Charkviani, Mariam , Kashani, Kianoush , May, Heather P. , Philpot, Lindsey M. , Rule, Andrew D.

Mayo Clinic

Nephrology Dialysis Transplantation | June 14, 2023 | Volume: 38 | Issue: Supplement_1 | Pages: No page available

10.1093/ndt/gfad063c_4573 Get It

Abstract Background and Aims At least 30% of acute kidney injury (AKI) survivors lack appropriate follow up after hospital discharge. AKI survivors have highly dynamic posthospital course which warrants close monitoring to prevent adverse outcomes. Digital health solutions like remote patient monitoring (RPM) could be used to improve quality and efficiency of AKI survivor care. The purpose for this study was to assess the feasibility and effectiveness of the Mayo Clinic AKI RPM program, launched in October 2021. Method The Mayo Clinic AKI RPM program enrolled individuals who experienced AKI during a hospitalization and underwent nephrology consultation (Figure 1). Feasibility was assessed as the proportion of individuals approached for AKI RPM enrollment during the first year of the program who submitted at least one set of vital signs after discharge. An effectiveness analysis compared stage 3 AKI survivors enrolled in AKI RPM with at least 30-days of follow-up to matched historical controls (3:1) sampled from before RPM was available (2018-2021). The primary endpoint was hospital readmission or emergency department (ED) visit within 30-days, assessed with the Chi-square test. Secondarily we explored time to first readmission or ED visit with a Kaplan-Meier survival curve with a non-parametric comparison between groups, as well as readmission length of stay with the Wilcoxon Rank Sum test due to right skewed data distribution. Results Of the 50 individuals approached for AKI RPM participation, 45 (90%) submitted at least one set of vitals. Among AKI RPM patients, 34 patients with stage 3 AKI were matched to 102 controls based on baseline characteristics and demographics. Dialysis during hospitalization (liberated by discharge) was used in 36 (27%) of patients. Sixty (44%) individuals required ICU level of care. Median (IQR) discharge estimated glomerular filtration rate was 15 (11, 27) mL/min/1.73m2. Through matching, groups were well balanced with respect to pertinent baseline demographics. Hospital readmission or ED visit occurred in 17 (50%) of AKI RPM patients within 30-days compared to 39 (38%) of controls within 30-days (P = .23). The endpoint appeared driven by ED visits within 30-days, not readmissions [At least one ED visit: 13 (38%) vs 21 (21%), respectively (P = .04); At least one hospital readmission: 7 (21%) vs 26 (26%), respectively (P = .56)]. Time to first readmission or ED visit within 30-days was similar between groups (P = .35; Figure 2). Among the 33 patients who were readmitted to the hospital within 30-days, readmission length of stay was similar in the AKI RPM group compared to controls [Median (IQR) 76 (10.6, 121) hours vs 108 (70, 165) hours); P = 0.33]. Conclusion In conclusion, AKI RPM was a feasible program when used to bridge the care continuum (hospital to home) in non-dialysis dependent AKI survivors. Incidence of at least one hospital readmission or ED visit within 30-days was statistically similar between AKI RPM patients and controls. More AKI RPM patients experienced ED encounters in the 30-days after discharge, but frequency of hospital readmission was similar. Digital health solutions such as RPM offer a unique opportunity to address the important gap in AKI care after discharging from the hospital. Additional research is needed to explore the impact of AKI RPM on patient outcomes.
Performance of Nuclear Magnetic Resonance-Based Estimated Glomerular Filtration Rate in a Real-World Setting
Santamaría, Amauri Schwäble , Grassi, M , Meeusen, Jeffrey W. , Lieske, John C. , Scott, Renee, Robertson, Andrew, Schiffer, Eric, Schwäble Santamaria, Amauri , Grassi, Marcello , Lieske, John C

Mayo Clinic

Bioengineering | June 14, 2023 | Volume: 10 | Issue: 6 | Pages: 717

10.3390/bioengineering10060717 | PMID 37370648 Get It

An accurate estimate of glomerular filtration rate (eGFR) is essential for proper clinical management, especially in patients with kidney dysfunction. This prospective observational study evaluated the real-world performance of the nuclear magnetic resonance (NMR)-based GFRNMR equation, which combines creatinine, cystatin C, valine, and myo-inositol with age and sex. We compared GFRNMR performance to that of the 2021 CKD-EPI creatinine and creatinine-cystatin C equations (CKD-EPI2021Cr and CKD-EPI2021CrCys), using 115 fresh routine samples of patients scheduled for urinary iothalamate clearance measurement (mGFR). Median bias to mGFR of the three eGFR equations was comparably low, ranging from 0.4 to 2.0 mL/min/1.73 m2. GFRNMR outperformed the 2021 CKD-EPI equations in terms of precision (interquartile range to mGFR of 10.5 vs. 17.9 mL/min/1.73 m2 for GFRNMR vs. CKD-EPI2021CrCys; p = 0.01) and accuracy (P15, P20, and P30 of 66.1% vs. 48.7% [p = 0.007], 80.0% vs. 60.0% [p < 0.001] and 95.7% vs. 86.1% [p = 0.006], respectively, for GFRNMR vs. CKD-EPI2021CrCys). Clinical parameters such as etiology, comorbidities, or medications did not significantly alter the performance of the three eGFR equations. Altogether, this study confirmed the utility of GFRNMR for accurate GFR estimation, and its potential value in routine clinical practice for improved medical care.
Primary cutaneous gamma/delta T‐cell lymphoma with simultaneous JAK2 and TP63 rearrangements: a new double‐hit?
Fadl, Amr, Comfere, Nneka I. , Greipp, Patricia T. , Feldman, Andrew L. , Feldman, Andrew L , Greipp, Patricia T , Bennani, N. Nora , Durani, Urshila

Mayo Clinic

Histopathology | June 13, 2023 | Volume: 83 | Issue: 3 | Pages: 492-495

10.1111/his.14973 | PMID 37308177 Get It

Comparison of clinical outcomes in patients with relapsed/refractory large B‐cell lymphoma treated with epcoritamab versus chemoimmunotherapy
Mutebi, Alex , Wang, T., Ma, Jun , Wang, A., Yu, Jinhua , Brodkin, Samantha, Kalsekar, Anupama, Ip, Andrew , Rosenthal, Allison , Wang, Trent , Yu, J., Sacchi, M., Muñoz, Javier

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 433-434

10.1002/hon.3164_319 Get It

THE PROGNOSTIC IMPACT OF CLINICAL FACTORS AND IMMUNOARCHITECTURAL PATTERNS FOR NODULAR LYMPHOCYTE‐PREDOMINANT HODGKIN LYMPHOMA: AN INTERNATIONAL STUDY BY GLOW
Binkley, Michael S., Borchmann, Peter , Fuchs, Michael , Hartmann, Sylvia , Eich, Hans Theodor, Skinnider, Brian, Steiner, Raphaël , Milgrom, Sarah A. , Alomari, Mohammed H., Zhang, Xieyi , Advani, Ranjana H. , Metzger, Monika L. , Wirth, A., Smith, Sonali M. , Hendrickson, P., Hopkins, David , Ng, Andrea K. , Koenig, Julie L. , Sakthivel, GD, Roberts, Kenneth B. , Gao, Sarah , Kendi, J. Al, Rahbi, Nasser Al, Balogh, Alex, Torka, Pallawi , Silva, Ravi De , Shah, Nimish , Osborne, Wendy , Henry, M M , Chang, Ilsung , Miall, Fiona , Brady, J.L. , Mikhaeel, G., Brennan, Barbara J. , Penn, Andrew M. , Сенченко, М. А. , Reeves, Mark E. , Terezakis, Stephanie , Fergusson, Pamela, Kelly, Kara M. , Advani, Ranjana H , Hopkins, David , Senchenko, Maria Anatolevna , Binkley, Michael S. , Flerlage, Jamie E. , Savage, Kerry J. , Hodgson, David C. , Akhtar, Saad , Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Vega, Francisco , Alomari, M., Zhang, X., Collins, Graham P. , Dickinson, Michael , Tsang, Richard , Prica, Anca A. , Major, Ajay , Kelsey, Chris R. , McKay, Pamela , Constine, Louis S , Casulo, Carla , Baron, J., Plastaras, John Peter , Kendi, J. Al, Levis, Mario , Ricardi, Umberto , Sridhar, A., Specht, Lena , Pickard, Keir , Blazin, Lindsay , Henry, M., Chang, I., Smith, Christine M , Halperin, Daniel M. , Brennan, B., Penn, A., Volchkov, Egor Vasilevich , Reeves, M., Hoppe, Bradford S. , Talaulikar, Dipti , Pepa, Roberta Della , Picardi, Marco , Kirova, Youlia , Fergusson, P., Northend, Michael , Shankar, Ananth , Maurer, Matthew J. , Natkunam, Yasodha , Eichenauer, Dennis A. , Hoppe, Richard T.

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 100-101

10.1002/hon.3163_62 Get It

COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB‐BASED REGIMENS, AND TAFASITAMAB‐BASED REGIMENS
Jun, Mira , Wang, T., Mutebi, Alex , Wang, A., Osei-Bonsu, Kojo, Elliott, Brian , Kalsekar, Anupama, Navarro, Fátima, Rosenthal, Allison , Jun, M., Muñoz, Javier , Wang, Trent , Su, Yang , Navarro, F. Rivas, Ip, Andrew

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 790-792

10.1002/hon.3165_639 Get It